Oric Pharmaceuticals, Inc. (ORIC)

ORIC's stock price experienced a significant drop of 41% on April 1, 2026, following a program update for rinzimetostat (ORIC-944) that indicated its prostate cancer treatment was roughly as effective as a competitor. The company announced it would proceed with a lower 400 mg dose of rinzimetostat in a global Phase 3 trial due to tolerability concerns. Over the past year, the share price has seen an increase of 68.95% as of May 4, 2026, compared to May 5, 2025. As of May 6, 2026, ORIC's stock price was $9.28. The company reported a net loss of $35.8 million for the quarter ended March 31, 2026, with increased R&D spending. Cash, cash equivalents, and investments reached $419.7 million as of March 31, 2026, partly due to $59.9 million raised through at-the-market offerings.

Demand seasonality for ORIC Pharmaceuticals' products and services is not a significant factor, as the company's target market is defined by specific cancer diagnoses and the presence of resistance mechanisms, rather than traditional demographic factors or seasonal patterns. ORIC's focus is on clinical and molecular profiles to identify patient populations for their cancer treatments.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies that overcome resistance mechanisms in cancer, operating within the Health Technology sector, specifically in the Pharmaceuticals: Major and Drug Discovery industries. The company is developing innovative small molecule therapies to address drug resistance in cancer. Its pipeline includes Rinzimetostat (ORIC-944) for prostate cancer, Enozertinib (ORIC-114) for multiple genetically defined cancers, particularly NSCLC, and ORIC-533 for multiple myeloma.

ORIC Pharmaceuticals is headquartered in South San Francisco, California, with additional offices in San Diego, California. The company's current geographical focus for its discovery and clinical development activities is primarily within the United States, but its ultimate commercialization strategy aims to reach major global oncology markets.

ORIC Pharmaceuticals' reputation has been affected by an investigation launched by Pomerantz LLP in May 2026, concerning whether ORIC and certain officers and/or directors engaged in securities fraud or other unlawful business practices. This investigation stems from the March 31, 2026, announcement regarding the rinzimetostat (ORIC-944) program update, which led to a significant drop in the company's stock price.

The ownership of ORIC Pharmaceuticals is largely institutional, with major institutional shareholders including EcoR1 Capital, LLC, Viking Global Investors Lp, BlackRock, Inc., VR Adviser, LLC, Pfizer Inc, Vanguard Group Inc, Sr One Capital Management, Lp, Alkeon Capital Management Llc, State Street Corp, and NEA Management Company, LLC. Other notable institutional investors include Nextech Invest, Ltd., Point72, Venrock Healthcare Capital Partners, Frazier Life Sciences Public Fund, L.P., and Column Group LLC. Institutional investors collectively hold a significant portion of ORIC Pharmaceuticals' shares, with 95.05% of the stock held by institutions. Insider ownership accounts for 6.82% of the shares.